The first and only all-human based screen for assessing the toxicity of drugs and chemical compounds on human development
45% of drugs in development fail due to safety concerns
devTOX™ stands Apart
In a blind study using hES cells as the test substrate and Stemina’s proprietary metabolimics platform to test 27 drugs with known birth-defect-causing effects, the devTOX™ assay predicted 7 of 8 drugs in each category. Traditional animal models perform with only about 60% accuracy.
devTOX™ benefits
More predictive
87.5% devTOX™ vs 60% animal model
Only all-human based screen
Non-subjective, quantitative endpoints; All-human pathway analysis
Confidence in compound selection
Choose compounds with lowest risk profile
Cost savings
Reduce compound attrition due to safety concerns (saving up to $70 million per drug)
Enables rapid decisions
Identify safety concerns earlier to enable rapid decision making
Reduces need for animal testing
Greater in vitro accuracy means fewer animal tests
An in vitro model for drug-induced cardiomyopathies
cardioTOX™ stands Apart
- Biomarkers of Cancer Stem Cells: Predictive Efficacy Screening in Cancer Stem Cells
Brain Tumor Stem Cells (BTSCs) are highly migratory, recapitulate tumors & are responsible for tumor recurrence. To cure cancer, BTSCs must be eradicated and to do so, we have identified:
- Biomarkers of efficacy against BTSCs
- Biomarkers of BTSCs (disease monitoring & earlier intervention)
- Potential drug targets for BTSC therapeutics
cardioTOX™ benefits
More predictive
Predictive metabolic signature of cardiomyopathy: cardiotoxicity is the reason for 30% of drug compound failures
Specific screening
Differenciation of cardiotoxic and non-cardiotoxic drug treatment combining hES cell derived cardiac precursors and metabolomics
Choose compounds with lowest risk profile
We invite you to 
Direct links
To contact us
Tools
Stay informed
